Salarius Pharmaceuticals Inc. (SLRX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
2450 HOLCOMBE BLVD HOUSTON, TX 77021 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 5,900 | 12,106 | 29,214 | 11,119 | 3,739 | 9,830 | |||
| Cash and cash equivalents | 5,900 | 12,106 | 29,214 | 11,119 | 3,739 | 9,830 | |||
| Restricted cash and investments | 127 | ||||||||
| Receivables | 1,610 | 1,600 | 3,856 | 10 | |||||
| Inventory, net of allowances, customer advances and progress billings | 187 | ||||||||
| Inventory | 187 | ||||||||
| Prepaid expense | 468 | 625 | 679 | 684 | 617 | ||||
| Other current assets | 151 | 168 | 173 | 138 | 136 | ||||
| Other undisclosed current assets | 11 | (1,502) | 203 | 162 | |||||
| Total current assets: | 6,520 | 14,520 | 30,164 | 15,797 | 4,695 | 10,315 | |||
| Noncurrent Assets | |||||||||
| Nontrade receivables | 1,610 | ||||||||
| Property, plant and equipment | 8 | 23 | 25 | 74 | |||||
| Intangible assets, net (including goodwill) | 8,866 | 8,866 | 8,866 | ||||||
| Goodwill | 8,866 | 8,866 | 8,866 | ||||||
| Other noncurrent assets | 67 | 131 | 186 | 247 | 309 | ||||
| Total noncurrent assets: | 67 | 131 | 10,670 | 9,136 | 9,200 | 74 | |||
| TOTAL ASSETS: | 6,587 | 14,651 | 40,834 | 24,932 | 13,894 | 10,390 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 603 | 2,858 | 1,543 | 1,854 | 1,791 | 1,035 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 418 | |||||
| Accounts payable | 603 | 2,858 | 1,543 | 1,854 | 1,791 | 343 | |||
| Accrued liabilities | 275 | ||||||||
| Deferred revenue | 542 | ✕ | |||||||
| Debt | 290 | 477 | 502 | ||||||
| Derivative instruments and hedges, liabilities | 15 | 59 | 318 | ||||||
| Restructuring reserve | 69 | ||||||||
| Other undisclosed current liabilities | 3 | ||||||||
| Total current liabilities: | 892 | 2,858 | 1,558 | 2,390 | 3,153 | 1,107 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed liabilities | 407 | 1,408 | 553 | 383 | 161 | ||||
| Total liabilities: | 1,299 | 4,266 | 2,111 | 2,773 | 3,314 | 1,107 | |||
| Equity | |||||||||
| Equity, attributable to parent | 5,287 | 10,385 | 38,723 | 22,159 | 10,581 | 9,283 | |||
| Common stock | 0 | 0 | 5 | 2 | 0 | 2 | |||
| Additional paid in capital | 81,635 | 74,190 | 70,916 | 41,586 | 22,657 | 142,242 | |||
| Accumulated deficit | (76,348) | (63,805) | (32,197) | (19,429) | (12,077) | (132,961) | |||
| Total equity: | 5,287 | 10,385 | 38,723 | 22,159 | 10,581 | 9,283 | |||
| TOTAL LIABILITIES AND EQUITY: | 6,587 | 14,651 | 40,834 | 24,932 | 13,894 | 10,390 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1,840 | 5,233 | 3,465 | 838 | ||||
| Net investment income | 152 | |||||||
| Cost of revenue (Cost of Goods and Services Sold) | (431) | |||||||
| Gross profit: | 1,840 | 5,233 | 3,465 | 407 | ||||
| Operating expenses | (12,895) | (31,841) | (14,653) | (13,020) | (11,730) | (22,912) | ||
| Other undisclosed operating income | 431 | |||||||
| Operating loss: | (12,895) | (31,841) | (12,813) | (7,786) | (8,265) | (22,074) | ||
| Nonoperating income (Other Nonoperating income) | 179 | |||||||
| Loss from continuing operations: | (12,895) | (31,841) | (12,813) | (7,608) | (8,265) | (22,074) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (12,813) | (7,608) | (8,265) | (22,074) | |
| Net loss: | (12,895) | (31,841) | (12,813) | (7,608) | (8,265) | (22,074) | ||
| Other undisclosed net income attributable to parent | 352 | 233 | 45 | 256 | 1,329 | 152 | ||
| Net loss attributable to parent: | (12,543) | (31,608) | (12,768) | (7,352) | (6,936) | (21,922) | ||
| Preferred stock dividends and other adjustments | (396) | |||||||
| Net loss available to common stockholders, diluted: | (12,543) | (31,608) | (12,768) | (7,749) | (6,936) | (21,922) | ||
Comprehensive Income ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (12,895) | (31,841) | (12,813) | (7,608) | (8,265) | (22,074) | ||
| Comprehensive loss: | (12,895) | (31,841) | (12,813) | (7,608) | (8,265) | (22,074) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 153 | |||||||
| Comprehensive loss, net of tax, attributable to parent: | (12,895) | (31,841) | (12,813) | (7,608) | (8,265) | (21,921) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.